Mineralys Therapeutics Inc
For the period ended Jun 30, 2024. Filed Aug 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 13, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
During the three months ended June 30, 2024, an affiliate of the Company, Samsara BioCapital, L.P. (Samsara), entered into a Rule 10b5-1 trading plan (the Samsara 10b5-1 Plan). The Samsara 10b5-1 Plan, entered into on May 3, 2024, is intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Exchange Act and provides for the sale of up to 1,691,638 shares of the Company’s common stock from time to time between August 12, 2024 and April 29, 2026. The Samsara 10b5-1 Plan will expire on April 29, 2026, or earlier if all shares under the plan are sold prior to that date. Srinivas Akkaraju, M.D., Ph.D., one of ourdirectors, is Managing General Partner of Samara and has voting and investment power over the shares held by Samsara.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.